Revised outcome - pursuant to typographical error founded in the outcome submitted on october 03, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals has resubmitted its October 3, 2025 board meeting outcome to correct a typographical error in the post-issue shareholding schedule. The board had approved a preferential issue of 46,43,000 convertible equity warrants to promoter group entities and individuals at Rs. 34 per warrant, aggregating to approximately Rs. 15.79 crore. Each warrant is convertible into one equity share within 18 months, with 25% payable upfront and 75% on conversion. Post-issue promoter shareholding rises marginally from 49.73% to 50.25%. The company has scheduled an EGM on November 1, 2025, to seek shareholder approval for the issue, with Mrs. Rupal Patel appointed as scrutinizer.
The warrant issue is relatively small (about 2.1% dilution on a fully diluted basis) and entirely to existing promoters, signaling promoter confidence and commitment of fresh capital rather than dilution to public shareholders. This is a minor capital infusion and unlikely to materially move the stock price; investors should watch the EGM outcome and any subsequent conversion announcements.